Develop Drugs News Today

BridgeBio Pharma (BBIO) said the first patient with non-small cell lung cancer ((NSCLC)) was dosed in a phase 1/2 trial of BBP-398 with Bristol Myers Squibb's (BMY) Opdivo (nivolumab)...

Xortx Therapeutics (XRTXF) (XRTX) reported data from a bridging pharmacokinetics trial of its proprietary formulation of oral oxypurinol, Xorlo being explored for kidney disease.The...

Relief Therapeutics (RLFTF)(RLFTD) reported six-month stability data on a new formulation of potential lung disease therapy RLF-100 (aviptadil).The company said the data showed high...

Galapagos has a new CEO since April 2022. The new strategy is taking shape with some research programs scrapped and small assets acquired. Read more here.

Intercept Pharmaceuticals (ICPT) stock fell ~18% on Sept

Akero Therapeutics (AKRO) said its drug efruxifermin ((EFX)) improved liver fibrosis without the worsening of liver disease, meeting the main goal of a Phase 2b study.The...

Biophytis (BPTS) said its drug Sarconeos was better at reducing the risk of respiratory failure or early death in patients with COVID-19,compared to placebo.The phase 2-3 study,...

AstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) presented detailed results from a 35-week interim analysis of a phase 3 trial of eplontersen, which had met its main goal, in...

BridgeBio Pharma's stock fell at the end of 2021 on some disappointing trial results. Read whether late-stage candidates and collaboration deals make BBIO a Buy.

72% technical buy signal. 15 new highs and up 59.18% in the last month. Price targets from $23 to $53. Click here to read more about FMTX stock.